Polyamine modulation of NMDARs as a mechanism to reduce effects of alcohol dependence

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 2, 2012, Pages 129-144

  Barron, Susan ^a   Lewis, Ben ^a   Wellmann, Kristen ^a   Carter, Megan ^a   Farook, Justin ^a   Ring, Josh ^b   Rogers, Dennis Trent ^a   Holley, Robert ^a   Crooks, Peter ^b   Littleton, John ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

NR2B neuroprotection; Polyamine; Relapse

Indexed keywords

4 (CHLOROBENZYLIDENAMINO)GUANIDINE HYDROCHLORIDE; ACAMPROSATE; AGMATINE; ALCOHOL; DIZOCILPINE; GLUTAMIC ACID; IFENPRODIL; JR 220; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; POLYAMINE; TOPIRAMATE; TRAXOPRODIL; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOL DEPRIVATION EFFECT; ALCOHOL WITHDRAWAL; ALCOHOLISM; ALZHEIMER DISEASE; CELL ASSAY; DRUG POTENCY; DRUG TARGETING; HUMAN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 84861732546     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912800673128     Document Type: Review

References (257)

1. Multiple Authors. National Epidemiologic Survey on Alcohol and Related Conditions. Summarized in Alcohol Alert. National Institute on Alcohol Abuse and Alcoholism. October 2006.
2. Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 2006; 101: 212-22.
3. Nevo I, Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995; 26: 305-36.
4. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010; 460: 525-42.
5. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004; 25: 265-72.
6. Lovinger DM, White G, Weight FF. Ethanol inhibits NMDAactivated ion current in hippocampal neurons. Sci 1989; 243: 1721-4.
7. Weiner JL, Dunwiddie TV, Valenzuela CF. Ethanol inhibition of synaptically evoked kainate responses in rat hippocampal CA3 pyramidal neurons. Mol Pharmacol 1999; 56: 85-90.
8. Tsai G. Glutamatergic neurotransmission in alcoholism. J Biomed Sci 1998; 5: 309-20.
9. Hoffman PL. NMDA receptors in alcoholism. Int Rev Neurobiol 2003; 56: 35-82.
10. Dildy-Mayfield JE, Harris RA. Comparison of ethanol sensitivity of rat brain kainate, DL-alpha-amino-3-hydroxy-5-methyl-4-isoxalone proprionic acid and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 1992; 262: 487-94.
11. Lovinger DM. Excitotoxicity and alcohol-related brain damage. Alcohol Clin Exp Res 1993; 17: 19-27.
12. Dildy-Mayfield JE, Harris RA. Ethanol inhibits kainate responses of glutamate receptors expressed in Xenopus oocytes: role of calcium and protein kinase C. J Neurosci 1995; 15: 3162-71.
13. Wirkner K, Eberts C, Poelchen W, Allgaier C, Illes P. Mechanism of inhibition by ethanol of NMDA and AMPA receptor channel functions in cultured rat cortical neurons. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 568-76.
14. Trussell LO, Thio LL, Zorumski CF, Fischbach GD. Rapid desensitization of glutamate receptors in vertebrate central neurons. Proc Natl Acad Sci USA 1988; 85: 4562-6.
15. Tang CM, Dichter M, Morad M. Quisqualate activates a rapidly inactivating high conductance ionic channel in hippocampal neurons. Sci 1989; 243: 1474-7.
16. Trussell LO, Fischbach GD. Glutamate receptor desensitization and its role in synaptic transmission. Neuron 1989; 3: 209-18.
17. Hestrin S. Activation and desensitization of glutamate-activated channels mediating fast excitatory synaptic currents in the visual cortex. Neuron 1992; 9: 991-9.
18. Barbour B, Keller BU, Llano I, Marty A. Prolonged presence of glutamate during excitatory synaptic transmission to cerebellar Purkinje cells. Neuron 1994; 12: 1331-43.
19. Moykkynen TP, Coleman SK, Keinanen K, Lovinger DM, Korpi ER. Ethanol increases desensitization of recombinant GluR-D AMPA receptor and TARP combinations. Alcohol 2009; 43: 277-84.
20. Peoples RW, White G, Lovinger DM, Weight FF. Ethanol inhibition of N-methyl-D-aspartate-activated current in mouse hippocampal neurones: whole-cell patch-clamp analysis. Br J Pharmacol 1997; 122: 1035-42.
21. Wirkner K, Poelchen W, Koles L, Muhlberg K, Scheibler P, Allgaier C, et al. Ethanol-induced inhibition of NMDA receptor channels. Neurochem Int 1999; 35: 153-62.
22. Davis KM, Wu JY. Role of glutamatergic and GABAergic systems in alcoholism. J Biomed Sci 2001; 8: 7-19.
23. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61.
24. Hetman M, Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem. 2006; 6: 787-99.
25. Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci 2009; 10: 126-40.
26. Collingridge GL, Lester RA. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 1989; 41: 143-210.
27. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 1990; 11: 290-6.
28. McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994; 74: 723-60.
29. Schorge S, Colquhoun D. Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J Neurosci 2003; 23: 1151-8.
30. Nakanishi S. Molecular diversity of the glutamate receptors. Clin Neuropharmacol 1992; 15 Suppl 1 Pt A: 4A-5A.
31. Wafford KA, Bain CJ, Le Bourdelles B, Whiting PJ, Kemp JA. Preferential co-assembly of recombinant NMDA receptors composed of three different subunits. Neuroreport 1993; 4: 1347-9.
32. Monaghan DT, Andaloro VJ, Skifter DA. Molecular determinants of NMDA receptor pharmacological diversity. Prog Brain Res 1998; 116: 171-90.
33. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11: 327-35.
34. Chung HJ, Huang YH, Lau LF, Huganir RL. Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J Neurosci 2004; 24: 10248-59.
35. Hoffman PL, Rabe CS, Moses F, Tabakoff B. N-methyl-Daspartate receptors and ethanol: inhibition of calcium flux and cyclic GMP production. J Neurochem 1989; 52: 1937-40.
36. Wright JM, Peoples RW, Weight FF. Single-channel and wholecell analysis of ethanol inhibition of NMDA-activated currents in cultured mouse cortical and hippocampal neurons. Brain Res 1996; 738: 249-56.
37. Woodward JJ, Pava MJ. Effects of ethanol on persistent activity and up-States in excitatory and inhibitory neurons in prefrontal cortex. Alcohol Clin Exp Res 2009; 33: 2134-40.
38. Calton JL, Wilson WA, Moore SD. Magnesium-dependent inhibition of N-methyl-D-aspartate receptor-mediated synaptic transmission by ethanol. J Pharmacol Exp Ther 1998; 287: 1015-9.
39. Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, Snyder GL, et al. DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. Nat Neurosci 2002; 5: 641-8.
40. Nie Z, Madamba SG, Siggins GR. Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms. J Pharmacol Exp Ther 1994; 271: 1566-73.
41. Yin HH, Park BS, Adermark L, Lovinger DM. Ethanol reverses the direction of long-term synaptic plasticity in the dorsomedial striatum. Eur J Neurosci 2007; 25: 3226-32.
42. Wang J, Carnicella S, Phamluong K, Jeanblanc J, Ronesi JA, Chaudhri N, et al. Ethanol induces long-term facilitation of NR2BNMDA receptor activity in the dorsal striatum: implications for alcohol drinking behavior. J Neurosci 2007; 27: 3593-602.
43. Popp RL, Lickteig R, Browning MD, Lovinger DM. Ethanol sensitivity and subunit composition of NMDA receptors in cultured striatal neurons. Neuropharmacology 1998; 37: 45-56.
44. Siggins GR, Martin G, Roberto M, Nie Z, Madamba S, De Lecea L. Glutamatergic transmission in opiate and alcohol dependence. Ann N Y Acad Sci 2003; 1003: 196-211.
45. Lovinger DM, White G, Weight FF. NMDA receptor-mediated synaptic excitation selectively inhibited by ethanol in hippocampal slice from adult rat. J Neurosci 1990; 10: 1372-9.
46. Morrisett RA, Martin D, Oetting TA, Lewis DV, Wilson WA, Swartzwelder HS. Ethanol and magnesium ions inhibit N-methyl-D-aspartate-mediated synaptic potentials in an interactive manner. Neuropharmacol 1991; 30: 1173-8.
47. Kolb JE, Trettel J, Levine ES. BDNF enhancement of postsynaptic NMDA receptors is blocked by ethanol. Synapse 2005; 55: 52-7.
48. Kuner T, Schoepfer R, Korpi ER. Ethanol inhibits glutamateinduced currents in heteromeric NMDA receptor subtypes. Neuroreport 1993; 5: 297-300.
49. Mirshahi T, Woodward J. Ethanol sensitivity of heteromeric NMDA receptors: effects of subunit assembly, glycine and NMDAR1 Mg(2+)-insensitive mutants. Neuropharmacol 1995; 34: 347-55.
50. Masood K, Wu C, Brauneis U, Weight FF. Differential ethanol sensitivity of recombinant N-methyl-D-aspartate receptor subunits. Mol Pharmacol 1994; 45: 324-9.
51. Allgaier C. Ethanol sensitivity of NMDA receptors. Neurochem Int 2002; 41: 377-82.
52. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996; 17: 348-55.
53. Tabakoff B, Hoffman PL. Alcohol addiction: an enigma among us. Neuron 1996; 16: 909-12.
54. Kumari M, Ticku MK. Regulation of NMDA receptors by ethanol. Prog Drug Res 2000; 54: 152-89.
55. Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol 1990; 176: 289-96.
56. Gulya K, Grant KA, Valverius P, Hoffman PL, Tabakoff B. Brain regional specificity and time-course of changes in the NMDA receptor-ionophore complex during ethanol withdrawal. Brain Res 1991; 547: 129-34.
57. Snell LD, Tabakoff B, Hoffman PL. Radioligand binding to the Nmethyl-D-aspartate receptor/ionophore complex: alterations by ethanol in vitro and by chronic in vivo ethanol ingestion. Brain Res 1993; 602: 91-8.
58. Follesa P, Ticku MK. Chronic ethanol treatment differentially regulates NMDA receptor subunit mRNA expression in rat brain. Mol Brain Res 1995; 29: 99-106.
59. Kalluri HS, Mehta AK, Ticku MK. Up-regulation of NMDA receptor subunits in rat brain following chronic ethanol treatment. Mol Brain Res 1998; 58: 221-4.
60. Hardy PA, Chen W, Wilce PA. Chronic ethanol exposure and withdrawal influence NMDA receptor subunit and splice variant mRNA expression in the rat cerebral cortex. Brain Res 1999; 819: 33-9.
61. Pian JP, Criado JR, Milner R, Ehlers CL. N-methyl-D-aspartate receptor subunit expression in adult and adolescent brain following chronic ethanol exposure. Neurosci 2010; 170: 645-54.
62. Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U, et al. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res 2005; 1052: 156-62.
63. Follesa P, Ticku MK. Chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptor polypeptide subunits in mouse cortical neurons in culture. J Biol Chem 1996; 271: 13297-9.
64. Chandler LJ, Sutton G, Norwood D, Sumners C, Crews FT. Chronic ethanol increases N-methyl-D-aspartate-stimulated nitric oxide formation but not receptor density in cultured cortical neurons. Mol Pharmacol 1997; 51: 733-40.
65. Narita M, Soma M, Mizoguchi H, Tseng LF, Suzuki T. Implications of the NR2B subunit-containing NMDA receptor localized in mouse limbic forebrain in ethanol dependence. Eur J Pharmacol 2000; 401: 191-5.
66. Biermann T, Reulbach U, Lenz B, Frieling H, Muschler M, Hillemacher T, et al. N-methyl-D-aspartate 2b receptor subtype (NR2B) promoter methylation in patients during alcohol withdrawal. J Neural Transm 2009; 116: 615-22.
67. Snell LD, Nunley KR, Lickteig RL, Browning MD, Tabakoff B, Hoffman PL. Regional and subunit specific changes in NMDA receptor mRNA and immunoreactivity in mouse brain following chronic ethanol ingestion. Mol Brain Res 1996; 40: 71-8.
68. Chandler LJ, Norwood D, Sutton G. Chronic ethanol upregulates NMDA and AMPA, but not kainate receptor subunit proteins in rat primary cortical cultures. Alcohol Clin Exp Res 1999; 23: 363-70.
69. Holter SM, Danysz W, Spanagel R. Novel uncompetitive Nmethyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure. J Pharmacol Exp Ther 2000; 292: 545-52.
70. Shelton KL, Balster RL. Effects of gamma-aminobutyric acid agonists and N-methyl-D-aspartate antagonists on a multiple schedule of ethanol and saccharin self-administration in rats. J Pharmacol Exp Ther 1997; 280: 1250-60.
71. Piasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P. Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur J Pharmacol 1998; 354: 135-43.
72. Bienkowski P, Koros E, Kostowski W, Danysz W. Effects of Nmethyl-D-aspartate receptor antagonists on reinforced and nonreinforced responding for ethanol in rats. Alcohol 1999; 18: 131-7.
73. Vengeliene V, Bachteler D, Danysz W, Spanagel R. The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacol 2005; 48: 822-9.
74. Boyce-Rustay JM, Cunningham CL. The role of NMDA receptor binding sites in ethanol place conditioning. Behav Neurosci 2004; 118: 822-34.
75. Biala G, Kotlinska J. Blockade of the acquisition of ethanolinduced conditioned place preference by N-methyl-D-aspartate receptor antagonists. Alcohol Alcohol 1999; 34: 175-82.
76. Broadbent J, Weitemier AZ. Dizocilpine (MK-801) prevents the development of sensitization to ethanol in DBA/2J mice. Alcohol Alcohol 1999; 34: 283-8.
77. Meyer PJ, Phillips TJ. Bivalent effects of MK-801 on ethanolinduced sensitization do not parallel its effects on ethanol-induced tolerance. Behav Neurosci 2003; 117: 641-9.
78. Mayer S, Harris BR, Gibson DA, Blanchard JA, Prendergast MA, Holley RC, et al. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res 2002; 26: 1468-78.
79. Morrisett RA, Rezvani AH, Overstreet D, Janowsky DS, Wilson WA, Swartzwelder HS. MK-801 potently inhibits alcohol withdrawal seizures in rats. Eur J Pharmacol 1990; 176: 103-5.
80. Prendergast MA, Harris BR, Mullholland PJ, Blanchard JA, 2nd, Gibson DA, Holley RC, et al. Hippocampal CA1 region neurodegeneration produced by ethanol withdrawal requires activation of intrinsic polysynaptic hippocampal pathways and function of N-methyl-D-aspartate receptors. Neurosci 2004; 124: 869-77.
81. Thomas J, Fleming And S, Riley E. MK-801 can exacerbate or attenuate behavioral alterations associated with neonatal alcohol exposure in the rat, depending on the timing of administration. Alcohol Clin Exp Res 2001; 25: 764-73.
82. Grant KA, Knisely JS, Tabakoff B, Barrett JE, Balster RL. Ethanol-like discriminative stimulus effects of non-competitive nmethyl-d-aspartate antagonists. Behav Pharmacol. 1991 2: 87-95.
83. Morita T, Sonoda R, Nakato K, Koshiya K, Wanibuchi F, Yamaguchi T. Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus. Psychopharmacol (Berl) 2000; 148: 281-8.
84. Klein M, Calderon S, Hayes B. Abuse liability assessment of neuroprotectants. Ann N Y Acad Sci 1999; 890: 515-25.
85. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Sci 1999; 283: 70-4.
86. Bender C, de Olmos S, Bueno A, de Olmos J, Lorenzo A. Comparative analyses of the neurodegeneration induced by the non-competitive NMDA-receptor-antagonist drug MK801 in mice and rats. Neurotoxicol Teratol 2010; 32: 542-50.
87. Stepanyan TD, Farook JM, Kowalski A, Kaplan E, Barron S, Littleton JM. Alcohol withdrawal-induced hippocampal neurotoxicity in vitro and seizures in vivo are both reduced by memantine. Alcohol Clin Exp Res 2008; 32: 2128-35.
88. Volbracht C, van Beek J, Zhu C, Blomgren K, Leist M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006; 23: 2611-22.
89. Kew JN, Kemp JA. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 1998; 512: 17-28.
90. Berger ML, Rebernik P. Zinc and ifenprodil allosterically inhibit two separate polyamine-sensitive sites at N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther 1999; 289: 1584-91.
91. Kew JN, Richards JG, Mutel V, Kemp JA. Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci 1998; 18: 1935-43.
92. Wang CX, Shuaib A. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord 2005; 4: 143-51.
93. Nash JE, Hill MP, Brotchie JM. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpinetreated rat. Exp Neurol 1999; 155: 42-8.
94. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000; 165: 136-42.
95. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr Pharm Des 2005; 11: 2977-94.
96. Tamura Y, Sato Y, Yokota T, Akaike A, Sasa M, Takaori S. Ifenprodil prevents glutamate cytotoxicity via polyamine modulatory sites of N-methyl-D-aspartate receptors in cultured cortical neurons. J Pharmacol Exp Ther 1993; 265: 1017-25.
97. Bath CP, Farrell LN, Gilmore J, Ward MA, Hicks CA, O'Neill MJ, et al. The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia. Eur J Pharmacol 1996; 299: 103-12.
98. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA 2005; 102: 443-8.
99. Toulmond S, Serrano A, Benavides J, Scatton B. Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window. Brain Res 1993; 620: 32-41.
100. Thomas JD, Garcia GG, Dominguez HD, Riley EP. Administration of eliprodil during ethanol withdrawal in the neonatal rat attenuates ethanol-induced learning deficits. Psychopharmacology (Berl) 2004; 175: 189-95.
101. Reyes M, Reyes A, Opitz T, Kapin MA, Stanton PK. Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slices from hypoxic/ischemic damage. Brain Res 1998; 782: 212-8.
102. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, et al. Separation of alpha 1 adrenergic and Nmethyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 1991; 34: 3085-90.
103. McCool BA, Lovinger DM. Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. Neuropharmacology 1995; 34: 621-9.
104. Biton B, Granger P, Carreau A, Depoortere H, Scatton B, Avenet P. The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical neurons. Eur J Pharmacol 1994; 257: 297-301.
105. Brimecombe JC, Boeckman FA, Aizenman E. Functional consequences of NR2 subunit composition in single recombinant N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 1997; 94: 11019-24.
106. Brimecombe JC, Gallagher MJ, Lynch DR, Aizenman E. An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1998; 286: 627-34.
107. Chazot PL, Lawrence S, Thompson CL. Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2Bselective NMDA receptor antagonists. Neuropharmacology 2002; 42: 319-24.
108. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38: 611-23.
109. Brackett RL, Pouw B, Blyden JF, Nour M, Matsumoto RR. Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology 2000; 39: 407-18.
110. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004; 188: 471-9.
111. Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol 2000; 163: 239-43.
112. Okiyama K, Smith DH, White WF, McIntosh TK. Effects of the NMDA antagonist CP-98,113 on regional cerebral edema and cardiovascular, cognitive, and neurobehavioral function following experimental brain injury in the rat. Brain Res 1998; 792: 291-8.
113. Tsuchida E, Rice M, Bullock R. The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma 1997; 14: 409-17.
114. Kundrotiene J, Cebers G, Wagner A, Liljequist S. The NMDA NR2B subunit-selective receptor antagonist, CP-101,606, enhances the functional recovery the NMDA NR2B subunit-selective receptor and reduces brain damage after cortical compressioninduced brain ischemia. J Neurotrauma 2004; 21: 83-93.
115. Menniti F, Chenard B, Collins M, Ducat M, Shalaby I, White F. CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur J Pharmacol 1997; 331: 117-26.
116. Nagy J. The NR2B subtype of NMDA receptor: a potential target for the treatment of alcohol dependence. Curr Drug Targets CNS Neurol Disord 2004; 3: 169-79.
117. Slotkin T, Bartolome J. Role of ornithine decarboxylase and the polyamines in nervous system development: a review. Brain Res Bull 1986; 17: 307-20.
118. Slotkin TA, Ferguson SA, Cada AM, McCook EC, Seidler FJ. Neonatal polyamine depletion by alpha-difluoromethylornithine: effects on adenylyl cyclase cell signaling are separable from effects on brain region growth. Brain Res 2000; 887: 16-22.
119. Davidson M, Wilce P. Chronic ethanol treatment leads to increased ornithine decarboxylase activity: implications for a role of polyamines in ethanol dependence and withdrawal. Alcohol Clin Exp Res 1998; 22: 1205-11.
120. Gibson DA, Harris BR, Prendergast MA, Hart SR, Blanchard JA, 2nd, Holley RC, et al. Polyamines contribute to ethanol withdrawal-induced neurotoxicity in rat hippocampal slice cultures through interactions with the NMDA receptor. Alcohol Clin Exp Res 2003; 27: 1099-106.
121. Thadani PV, Lau C, Slotkin TA, Schanberg SM. Effect of maternal ethanol ingestion on neonatal rat brain and heart ornithine decarboxylase. Biochem Pharmacol 1977; 26: 523-7.
122. Shibley IA, Jr., Gavigan MD, Pennington SN. Ethanol's effect on tissue polyamines and ornithine decarboxylase activity: a concise review. Alcohol Clin Exp Res 1995; 19: 209-15.
123. Davidson MD, Wilce P, Shanley BC. Increased sensitivity of the hippocampus in ethanol-dependent rats to toxic effect of N-methyl-D-aspartic acid in vivo. Brain Res 1993; 606: 5-9.
124. Butler TR, Self RL, Smith KJ, Sharrett-Field LJ, Berry JN, Littleton JM, et al. Selective vulnerability of hippocampal cornu ammonis 1 pyramidal cells to excitotoxic insult is associated with the expression of polyamine-sensitive N-methyl-D-asparate-type glutamate receptors. Neuroscience 2010; 165: 525-34.
125. Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 2003; 27: 232-43.
126. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 1998; 22: 13-24.
127. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003; 12 Suppl 1: S3-11.
128. Staner L, Boeijinga P, Danel T, Gendre I, Muzet M, Landron F, et al. Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcohol Clin Exp Res 2006; 30: 1492-9.
129. Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol 2007; 21: 9-28.
130. Miller WR. What is a relapse? Fifty ways to leave the wagon. Addiction 1996; 91 Suppl: S15-27.
131. Connors GJ, Maisto SA, Donovan DM. Conceptualizations of relapse: a summary of psychological and psychobiological models. Addiction 1996; 91 Suppl: S5-13.
132. Solomon RL. The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Am Psychol 1980; 35: 691-712.
133. O'Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol 1998; 12: 15-22.
134. Valdez GR, Zorrilla EP, Roberts AJ, Koob GF. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 2003; 29: 55-60.
135. Kelley AE, Smith-Roe SL, Holahan MR. Response-reinforcement learning is dependent on N-methyl-D-aspartate receptor activation in the nucleus accumbens core. Proc Natl Acad Sci USA 1997; 94: 12174-9.
136. Gewirtz JC, Davis M. Second-order fear conditioning prevented by blocking NMDA receptors in amygdala. Nature 1997; 388: 471-4.
137. Maren S. Synaptic transmission and plasticity in the amygdala. An emerging physiology of fear conditioning circuits. Mol Neurobiol 1996; 13: 1-22.
138. Stout RL, Longabaugh R, Rubin A. Predictive validity of Marlatt's relapse taxonomy versus a more general relapse code. Addiction 1996; 91 Suppl: S99-110.
139. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239-47.
140. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-80.
141. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996; 13: 35-9.
142. Modesto-Lowe V, Burleson JA, Hersh D, Bauer LO, Kranzler HR. Effects of naltrexone on cue-elicited craving for alcohol and cocaine. Drug Alcohol Depend 1997; 49: 9-16.
143. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997; 18: 54-9.
144. Putzke J, Spanagel R, Tolle TR, Zieglgansberger W. The anticraving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol 1996; 317: 39-48.
145. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996; 305: 39-44.
146. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998; 18: 125-33.
147. Cole JC, Littleton JM, Little HJ. Effects of repeated ethanol administration in the plus maze; a simple model for conditioned abstinence behaviour. Psychopharmacology (Berl) 1999; 142: 270-9.
148. Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 2005; 30: 1104-10.
149. Mason BJ, Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother 2007; 7: 1465-77.
150. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Sys Rev 2010; CD004332.
151. Honkanen A, Vilamo L, Wegelius K, Sarviharju M, Hyytia P, Korpi ER. Alcohol drinking is reduced by a mu1-but not by a delta-opioid receptor antagonist in alcohol-preferring rats. Eur J Pharmacol 1996; 304: 7-13.
152. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998; 22: 802-9.
153. Al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998; 22: 810-4.
154. Littleton JM. Acamprosate in alcohol dependence: Implications of a unique mechanism of action. Journal of Addiction Medicine 2007; 1: 115-25 10
155. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002; 26: 1779-93.
156. Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 2007; 164: 519-23.
157. Rammes G, Schierloh A. Neramexane (Merz Pharmaceuticals/Forest Laboratories). Drugs 2006; 9: 128-35.
158. McMillen BA, Crawford MS, Kulers CM, Williams HL. Effects of a metabotropic, mGlu5, glutamate receptor antagonist on ethanol consumption by genetic drinking rats. Alcohol Alcohol 2005; 40: 494-7.
159. Zhao Y, Dayas CV, Aujla H, Baptista MA, Martin-Fardon R, Weiss F. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci 2006; 26: 9967-74.
160. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5: 3-14.
161. Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol 2007; 42: 296-300.
162. Johnson BA. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Exp Opin Pharmacother 2004; 5: 1943-55.
163. Harper C, Dixon G, Sheedy D, Garrick T. Neuropathological alterations in alcoholic brains. Studies arising from the New South Wales Tissue Resource Centre. Prog Neuropsychopharmacology Biol Psychiatry 2003; 27: 951-61.
164. Crews FT, Collins MA, Dlugos C, Littleton J, Wilkins L, Neafsey EJ, et al. Alcohol-induced neurodegeneration: when, where and why? Alcohol Clin Exp Res 2004; 28: 350-64.
165. Booth BM, Blow FC. The kindling hypothesis: further evidence from a U.S. national study of alcoholic men. Alcohol Alcohol 1993; 28: 593-8.
166. Duka T, Townshend JM, Collier K, Stephens DN. Impairment in cognitive functions after multiple detoxifications in alcoholic inpatients. Alcohol Clin Exp Res 2003; 27: 1563-72.
167. McCrady BS, Smith DE. Implications of cognitive impairment for the treatment of alcoholism. Alcohol Clin Exp Res 1986; 10: 145-9.
168. Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 2002; 26: 586-92.
169. Al Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res; 2001: 1276-83.
170. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007; 8: 621-32.
171. Schubert S, Brandl U, Brodhun M, Ulrich C, Spaltmann J, Fiedler N, et al. Neuroprotective effects of topiramate after hypoxiaischemia in newborn piglets. Brain Res 2005; 1058: 129-36.
172. Harris BR, Gibson DA, Prendergast MA, Blanchard JA, Holley RC, Hart SR, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res 2003; 27: 1724-35.
173. Low SJ, Roland CL. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther 2004; 42: 1-14.
174. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 1998; 11: 523-69.
175. Hundt W, Danysz W, Holter SM, Spanagel R. Ethanol and Nmethyl-D-aspartate receptor complex interactions: a detailed drug discrimination study in the rat. Psychopharmacology (Berl) 1998; 135: 44-51.
176. Rock DM, Macdonald RL. Polyamine regulation of N-methyl-Daspartate receptor channels. Annu Rev Pharmacol Toxicol 1995; 35: 463-82.
177. Bergeron RJ, Weimar WR, Wu Q, Feng Y, McManis JS. Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study. J Med Chem 1996; 39: 5257-66.
178. Ransom RW, Deschenes NL. Polyamines regulate glycine interaction with the N-methyl-D-aspartate receptor. Synapse 1990; 5: 294-8.
179. Lewin AH, Sun G, Fudala L, Navarro H, Zhou LM, Popik P, et al. Molecular features associated with polyamine modulation of NMDA receptors. J Med Chem 1998; 41: 988-95.
180. Romano C, Williams K, DePriest S, Seshadri R, Marshall GR, Israel M, et al. Effects of mono-, di-, and triamines on the Nmethyl-D-aspartate receptor complex: a model of the polyamine recognition site. Mol Pharmacol 1992; 41: 785-92.
181. Berger ML, Seifriz I, Letschnig M, Schodl C, Noe CR. Interaction of long chain n-alkyl diamines with the NMDA receptor complex. Neurosci Lett 1992; 142: 85-8.
182. Gibson DA, Harris BR, Rogers DT, Littleton JM. Radioligand binding studies reveal agmatine is a more selective antagonist for a polyamine-site on the NMDA receptor than arcaine or ifenprodil. Brain Res 2002; 952: 71-7.
183. Gilad GM, Salame K, Rabey JM, Gilad VH. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 1996; 58: 41-6.
184. Morgan AD, Campbell UC, Fons RD, Carroll ME. Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol Biochem Behav 2002; 72: 873-80.
185. Levi MS, Borne RF. A review of chemical agents in the pharmacotherapy of addiction. Curr Med Chem 2002; 9: 1807-18.
186. Skolnick P. Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties. Alkaloids Chem Biol 2001; 56: 55-62.
187. Worthen DR, Gibson DA, Rogers DT, Bence AK, Fu M, Littleton JM, et al. Endogenous indoles as novel polyamine site ligands at the N-methyl-D-aspartate receptor complex. Brain Res 2001; 890: 343-6.
188. Mundy WR, Radio NM, Freudenrich TM. Neuronal models for evaluation of proliferation in vitro using high content screening. Toxicol 2010; 270: 121-30.
189. Ahern KB, Lustig HS, Greenberg DA. Enhancement of NMDA toxicity and calcium responses by chronic exposure of cultured cortical neurons to ethanol. Neurosci Lett 1994; 165: 211-4.
190. Prendergast MA, Harris BR, Blanchard JA, 2nd, Mayer S, Gibson DA, Littleton JM. In vitro effects of ethanol withdrawal and spermidine on viability of hippocampus from male and female rat. Alcohol Clin Exp Res 2000; 24: 1855-61.
191. Farook JM, Krazem A, Lewis B, Morrell DJ, Littleton JM, Barron S. Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice. Physiol Behav 2008; 95: 267-70.
192. Crabbe JC, Young ER, Janowsky J, Rigter H. Pyrazole exacerbates handling-induced convulsions in mice. Neuropharmacology 1981; 20: 605-9.
193. Sinclair JD, Senter RJ. Increased preference for ethanol in rats following alcohol deprivation. Psychonomic Science 1967; 8: 11-2.
194. File SE. New strategies in the search for anxiolytics. Drug Des Deliv 1990; 5: 195-201.
195. Cole JC, Littleton JM, Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology (Berl) 2000; 147: 403-11.
196. Kamdar NK, Miller SA, Syed YM, Bhayana R, Gupta T, Rhodes JS. Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice. Psychopharmacology (Berl) 2007; 192: 207-17.
197. Gupta T, Syed YM, Revis AA, Miller SA, Martinez M, Cohn KA, et al. Acute effects of acamprosate and MPEP on ethanol Drinkingin-the-Dark in male C57BL/6J mice. Alcohol Clin Exp Res 2008; 32: 1992-8.
198. Sampson PD, Streissguth AP, Bookstein FL, Little RE, Clarren SK, Dehaene P, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology 1997; 56: 317-26.
199. Williams R, Odaibo F, McGee J. Incidence of fetal alcohol syndrome in northeastern Manitoba. Can J Public Health 1999; 90: 192-4.
200. Lupton C, Burd L, Harwood R. Cost of fetal alcohol spectrum disorders. Am J Med Genet C Semin Med Genet 2004; 127C: 42-50.
201. Helfer JL, Goodlett CR, Greenough WT, Klintsova AY. The effects of exercise on adolescent hippocampal neurogenesis in a rat model of binge alcohol exposure during the brain growth spurt. Brain Res 2009; 1294: 1-11.
202. Thomas JD, Idrus NM, Monk BR, Dominguez HD. Prenatal choline supplementation mitigates behavioral alterations associated with prenatal alcohol exposure in rats. Birth Defects Res A Clin Mol Teratol 2010; 88: 827-37.
203. Wilkemeyer MF, Menkari CE, Charness ME. Novel antagonists of alcohol inhibition of l1-mediated cell adhesion: multiple mechanisms of action. Mol Pharmacol 2002; 62: 1053-60.
204. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med 2005; 9: 623-42.
205. Sircar R. Developmental maturation of the N-methyl-D-aspartic acid receptor channel complex in postnatal rat brain. Int J Dev Neurosci 2000; 18: 121-31.
206. Davidson M, Bedi K, Wilce P. Ethanol inhibition of brain ornithine decarboxylase activity in the postnatal rat. Neurotoxicol Teratol 1998; 20: 523-30.
207. Thadani P, Slotkin T, Schanberg S. Effects of late prenatal or early postnatal ethanol exposure on ornithine decarboxylase activity in brain and heart of developing rats. Neuropharmacology 1977; 16: 289-93.
208. Williams K, Zappia A, Pritchett D, Shen Y, Molinoff P. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol Pharmacol 1994; 45: 803-9.
209. Naassila M, Daoust M. Effect of prenatal and postnatal ethanol exposure on the developmental profile of mRNAs encoding NMDA receptor subunits in rat hippocampus. J Neurochem 2002; 80: 850-60.
210. Williams K, Russell SL, Shen YM, Molinoff PB. Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 1993; 10: 267-78.
211. Barron S, Mulholland PJ, Littleton JM, Prendergast MA. Age and gender differences in response to neonatal ethanol withdrawal and polyamine challenge in organotypic hippocampal cultures. Alcohol Clin Exp Res 2008; 32: 929-36.
212. Lewis B, Wellmann KA, Kehrberg AMH, Carter ML, Baldwin T, Cohen M, et al. Behavioral deficits and cellular damage following developmental ethanol exposure in rats are attenuated by CP-101,606, an NMDAR antagonist with unique NR2B specificity. Submitted.
213. Wellmann KA, Lewis B, Carter LG, Carter ML, McGahan J, Crooks PA, et al. JR 220, a novel aminoguanadino compound, ameliorates ultrasonic vocalization and balance deficits in rats following "3rd trimester" ethanol exposure. Submitted.
214. Rubin MA, Wellmann KA, Lewis B, Overgaauw BJ, Littleton JM, Barron S. Difluoromethylornithine (DFMO) reduces deficits in isolation-induced ultrasonic vocalizations and balance following neonatal ethanol exposure in rats. Pharmacol Biochem Behav 2009; 92: 44-50.
215. Wellmann K, Lewis B, Barron S. Agmatine reduces ultrasonic vocalization deficits in female rat pups exposed neonatally to ethanol. Neurotoxicol Teratol 2010; 32: 158-63.
216. Lewis B, Wellmann KA, Barron S. Agmatine reduces balance deficits in a rat model of third trimester binge-like ethanol exposure. Pharmacol Biochem Behav 2007; 88: 114-21.
217. Heyser CJ, Moc K, Koob, GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacol 2003; 28: 1463-71.
218. Gabriel KI, Cunningham CL. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res 2005; 29: 75-80.
219. Uzbay IT, Yeilyurt O, Celik T, Ergün H, Iimer A. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res 2000; 107: 153-9.
220. Zakharova E, Malyshkin A, Kashkin V, Neznanova O, Sukhotina I, Danysz W, et al. The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats. Behav Pharmacol 2004; 15: 273-8.
221. Jandeleit, B., Li, Y., Gallop, M.A., Zerangue, N., Virsik, P.A., Fischer, W.-N. Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use. US0069419 (2009).
222. Jandeleit, B., Li, Y., Gallop, M.A., Zerangue, N., Virsik, P.A., Fischer, W.-N. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use. US0076147 (2009).
223. Jandeleit, B., Li, Y., Gallop, M.A., Zerangue, N., Virsik, P.A., Fischer, W.-N. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use. US0082464 (2009).
224. Jandeleit, B., Li, Y., Gallop, M.A., Zerangue, N., Virsik, P.A., Fischer, W.-N. Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use. US7994218 (2011).
225. Li, Y., Jandeleit, B., Gallop, M.A., Zerangue, N., Virsik, P.A., Fischer, W.-N. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use. US0099253 (2009).
226. Arellano, M.B.F. Compounds used to treat alcoholism. MX011864 (2005).
227. Bilbeny, L.N., Garcia, M.H. Amines with antialcoholic agents. WO03026634 (2003).
228. Bilbeny, L.N., Garcia, M.H. Amines as anti-alcoholism agents. US7232846 (2007).
229. Bachurin, S.O., Gavrilova, S.I., Grigoriev, V.V., Beznosko, B.K., Zefirov, N.S. Means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-B) indoles (variants), pharmacological means based thereon and method for the use thereof. WO2008069963 (2008).
230. Gerlach, M., Przewosny, M., Englberger, W., Reissmueller, E., Bloms-Funke, P., Maul, C., Jagusch, U.-P. Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives. US6699877 (2004).
231. Kawamura, M. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists. US6713490 (2004).
232. Masui, M., Adachi, M., Mikamiyama, H., Matsumura, A., Tsuno, N. Nitrogen-containing heterocycle derivatives substituted with cyclic group. US7935706 (2011).
233. Wong, A.J. Alternative splice forms of proteins as basis for multiple therapeutic. US8021658 (2011).
234. Kuehnert, S., Zemolka, S., Hauraud, M., Schiene, K. Substituted imidazo[2,1-b]thiazole compounds and uses thereof. US7893069 (2011).
235. Haurand, M., Schiene, K., Kiihnert, S., Reich, M., Zemolka, S. Substituted propiolic acid amides and their use for producing drugs. US8008304 (2011a).
236. Haurand, M., Schiene, K., Kühnert Reich, M. Substituted thiazoles and their use for producing drugs. US7871999 (2011b).
237. Bridges RJ, Esslinger CS. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 2005; 107:271-285.
238. Bohm, A., Dubroeucq, M.-C., Fratta, W., Guyon, C., Imperato, A., Manfre, F. Application of pyrrolidine derivatives to the preparation of medicaments intended to the treatment of drug abuse. EP0879054 (2007).
239. Imperato, A. Use of pyrrolidine derivatives for treating alcoholism. NZ310488 (2000).
240. Imperato, A. The use of pyrrolidine derivatives for the treatment of alcoholism. BG0063189 (2001a).
241. Imperato, A. Use of pyrrolidine derivatives for preparation of medicament for treating alcoholism. SK0282063 (2001b).
242. Imperato, A. Method for treating chronic alcoholism or conditions caused by alcohol abuse. RO0117297 (2002a).
243. Imperato, A. Use of pyrrolidine derivatives for treating alcoholism. SI0828486 (2002b).
244. Imperato, A. Use of pyrrolidine derivatives for treating alcoholism. EP0828486 (2002c).
245. Imperato, A. Use of pyrrolidine derivatives for treating alcoholism. CA2219455 (2009).
246. Nilsson, L., Rogers, G.A. Benzoyl piperidines/pyrrolidines for enhancing synaptic response. CA2222976 (2001).
247. Rogers, G.A., Nilsson, L. Benzoyl piperidines/pyrrolidines for enhancing synaptic response. EP0839134 (2004).
248. nd. Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists. EA0001963 (2001).
249. Chenard, B.L., Welch, W.M., Weinhold, A.R. Thieno-pyrimidin-4-one AMPA antagonists. US6921764 (2005).
250. Ciruela F, Gomez-Soler M, Guidolin D, Borroto-Escuela DO, Agnati LF, Fuxe K, et al. Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission. Biochimica et Biophysica Acta 2011; 1808:1245-55.
251. Liang, B.T., Jacobson, K.A. Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists. US6586413 (2003).
252. Shook, B.C., Jackson, P.F. Arylindenopyrimidines compound and use as an adenosine A2a receptor antagonists. US8017614 (2011).
253. Eisenbach-Schwartz, M., Yoles, E., Sorek, N., Hauben, E. Poly-Glu, Tyr for neuroprotective therapy. US7399740 (2008).
254. Feuerstein, T.J., Knoerle, R. Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate. US6384069 (2002).
255. Feuerstein, T.J., Knoerle, R. 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level. US6984659 (2006).
256. Slusher, B.S., Tsukamoto, T. Thiolactones. US7125907 (2006).
257. Jackson, P.F., Tsukamoto, T., Slusher, B.S., Wang, E. Benzenedicarboxylic acid derivatives. US6452044 (2002).